id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-130351-w9mij6c6	Mamidala, Estari	In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of covid-19	2020-04-25		.txt	text/plain	2676	155	50	In the present study, we report the potential inhibitory activity of some FDA approved drugs against SARS-CoV-2 main protease by molecular docking study to investigate their binding affinity in protease active site. Docking studies revealed that drug Oseltamivir (anti-H1N1 drug), Rifampin (anti-TB drug), Maraviroc, Etravirine, Indinavir, Rilpivirine (anti-HIV drugs) and Atovaquone, Quinidine, Halofantrine, Amodiaquine, Tetracylcine, Azithromycin, hydroxycholoroquine (anti-malarial drugs) among others binds in the active site of the protease with similar or higher affinity. 11 The free energy (DG) binding of SARS-CoV-2 viral protease with the selected FDA approved drugs was created by means of this molecular docking package. Oseltamivir and Zanamivir, two FDA approved drugs docked with SARS-CoV-2 main protease and obtained binding energy is −7.39 kcal/mol and -3.88 kcal/mol respectively (Table-2 Figure 2 ).	./cache/cord-130351-w9mij6c6.txt	./txt/cord-130351-w9mij6c6.txt